Danielle R Rios1, Brady S Moffett2, Jeffrey R Kaiser3. 1. Section of Neonatology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX. Electronic address: drrios@texaschildrens.org. 2. Department of Pharmacy, Texas Children's Hospital, Houston, TX. 3. Section of Neonatology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX; Department of Obstetrics and Gynecology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.
Abstract
OBJECTIVE: To determine trends in pharmacotherapy for neonatal hypotension in all infants and in extremely low birth weight (ELBW, birth weight 300-1000 g) infants. STUDY DESIGN: We queried the Pediatric Health Information System database for all infants ≤28 days with a diagnosis code for hypotension that were discharged between January 2001 and December 2012. Patients were excluded if they had complex congenital heart disease or cardiac surgery, sepsis or meningitis, or had extracorporeal membrane oxygenation. We determined trends in pharmacotherapy for hypotension in all infants and ELBW infants, an especially vulnerable group. RESULTS: A total of 8019 hypotensive infants met study criteria. The 2 most prescribed medications were dopamine (65.3%) and dobutamine (19.9%). For 1487 hypotensive ELBW infants, the 2 most prescribed medications were dopamine (83.4%) and hydrocortisone (33%). During the study period, the use of dobutamine decreased, and hydrocortisone and vasopressin use increased for all infants and for ELBW infants. CONCLUSIONS: Treatment of neonatal hypotension varies widely between institutions and individual practitioners, and pharmacotherapy for neonatal hypotension has changed over the past decade. Although dopamine and dobutamine were the most frequently used agents, their use has declined and the uses of hydrocortisone and vasopressin have increased.
OBJECTIVE: To determine trends in pharmacotherapy for neonatal hypotension in all infants and in extremely low birth weight (ELBW, birth weight 300-1000 g) infants. STUDY DESIGN: We queried the Pediatric Health Information System database for all infants ≤28 days with a diagnosis code for hypotension that were discharged between January 2001 and December 2012. Patients were excluded if they had complex congenital heart disease or cardiac surgery, sepsis or meningitis, or had extracorporeal membrane oxygenation. We determined trends in pharmacotherapy for hypotension in all infants and ELBW infants, an especially vulnerable group. RESULTS: A total of 8019 hypotensiveinfants met study criteria. The 2 most prescribed medications were dopamine (65.3%) and dobutamine (19.9%). For 1487 hypotensive ELBW infants, the 2 most prescribed medications were dopamine (83.4%) and hydrocortisone (33%). During the study period, the use of dobutamine decreased, and hydrocortisone and vasopressin use increased for all infants and for ELBW infants. CONCLUSIONS: Treatment of neonatal hypotension varies widely between institutions and individual practitioners, and pharmacotherapy for neonatal hypotension has changed over the past decade. Although dopamine and dobutamine were the most frequently used agents, their use has declined and the uses of hydrocortisone and vasopressin have increased.
Authors: Mengwei Ni; Jeffrey R Kaiser; Brady S Moffett; Christopher J Rhee; Jennifer Placencia; Kimberly L Dinh; Joseph L Hagan; Danielle R Rios Journal: J Pediatr Pharmacol Ther Date: 2017 Nov-Dec
Authors: Ningxin Luo; Siyuan Jiang; Patrick J McNamara; Xiaoying Li; Yan Guo; Yang Wang; Junyan Han; Yingping Deng; Yi Yang; Shoo K Lee; Yun Cao Journal: Front Pediatr Date: 2021-04-22 Impact factor: 3.418
Authors: Laura E Miller; Matthew M Laughon; Reese H Clark; Kanecia O Zimmerman; Christoph P Hornik; Samia Aleem; P Brian Smith; Rachel G Greenberg Journal: J Perinatol Date: 2021-03-23 Impact factor: 3.225
Authors: Abdulrahman Salim Alsaadi; Katelyn Sushko; Vivian Bui; John Van Den Anker; Abdul Razak; Samira Samiee-Zafarghandy Journal: BMJ Paediatr Open Date: 2021-06-09